DXCM
DexCom, Inc. (Nasdaq 100, S&P 500)
Healthcare — Medical Devices
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $28.88B |
| P/E Ratio (TTM) | 32.12 |
| Forward P/E | 24.32 |
| EPS (TTM) | $2.33 |
| Dividend Yield | - |
| Profit Margin | 19.31% |
| Revenue Growth | 15.00% |
| ROE | 35.62% |
| Debt/Equity | 46.83 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $86.16 |
| Analysts | 25 |
| Indexes | Nasdaq 100 S&P 500 |
Technical Indicators
| RSI (14) | 51.6 |
| Beta | 1.45 |
| SMA 20 | $73.27 |
| SMA 40 | $72.99 |
| 52-Week High | $89.98 |
| 52-Week Low | $54.11 |
| 50-Day Avg | $72.00 |
| 200-Day Avg | $67.54 |
| Avg Volume | $5.72M |
| Volume | $3.99M |
Performance Analysis
BULLISHDXCM shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 28, 2026 21:00 UTC
Back to Screener Export Report